phone

Community Acquired Pneumonia - Pipeline Review, H2 2017

  • Published Date: 18 Jul 2017
  • Number of Pages: 106
  • Category: Pharmaceuticals
  • Country: Global
Community Acquired Pneumonia - Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Community Acquired Pneumonia - Pipeline Review, H2 2017, provides an overview of the Community Acquired Pneumonia (Infectious Disease) pipeline landscape.

Community-acquired pneumonia (CAP) is defined as pneumonia acquired outside a hospital or long-term care facility. Symptoms include cough, fever, shaking chills, confusion, headache and loss of appetite. Risk factors include chronic lung disease, cigarette smoking, dementia, stroke, brain injury, heart disease, liver cirrhosis and diabetes mellitus. Treatment includes antibiotics and healthy lifestyle.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Community Acquired Pneumonia - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Community Acquired Pneumonia (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Community Acquired Pneumonia (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Community Acquired Pneumonia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 3, 6, 2, 1 and 1 respectively.

Community Acquired Pneumonia (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Community Acquired Pneumonia (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Community Acquired Pneumonia (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Community Acquired Pneumonia (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Community Acquired Pneumonia (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Community Acquired Pneumonia (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Community Acquired Pneumonia (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Community Acquired Pneumonia (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Publisher Name : Global Markets Direct

Introduction
Global Markets Direct Report Coverage
Community Acquired Pneumonia - Overview
Community Acquired Pneumonia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Community Acquired Pneumonia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Community Acquired Pneumonia - Companies Involved in Therapeutics Development
Aridis Pharmaceuticals LLC
Biotest AG
InflaRx GmbH
ioGenetics Inc
Kyorin Pharmaceutical Co Ltd
Melinta Therapeutics Inc
Merck & Co Inc
Nabriva Therapeutics AG
Paratek Pharmaceuticals Inc
TaiGen Biotechnology Co Ltd
Takeda Pharmaceutical Company Ltd
Tetraphase Pharmaceuticals Inc
TiGenix NV
Wockhardt Ltd
Community Acquired Pneumonia - Drug Profiles
BT-086 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CAL-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ceftaroline fosamil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cx-611 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DBAF-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
delafloxacin meglumine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IFX-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lascufloxacin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lefamulin acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nafithromycin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nemonoxacin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
omadacycline tosylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PneumoMab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Plasma Gelsolin Replacement for Community Acquired Pneumonia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
solithromycin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tosatoxumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TP-271 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Community Acquired Pneumonia - Dormant Projects
Community Acquired Pneumonia - Discontinued Products
Community Acquired Pneumonia - Product Development Milestones
Featured News & Press Releases
Jun 05, 2017: Nabriva Therapeutics Announces Webcast of Analyst & Investor Day on June 19, 2017
Jun 02, 2017: Nabriva Therapeutics to present data at ASM Microbe supporting ongoing Phase 3 clinical development program for lefamulin
Jun 02, 2017: Eight Presentations at ASM Microbe Include Late Breaker From Cempras Phase 3 Fusidic Acid Study and Solithromycin Data on Gonorrhea and Otitis Media
May 30, 2017: TaiGen Biotechnology Announces Submission of New Drug Application for Taigexyn Intravenous Formulation to the China Food and Drug Administration
Apr 25, 2017: Omadacycline Concentrations Exceed Tigecycline Levels in Lungs and Epithelial Lining Fluid According to Pharmacokinetic/Pharmacodynamic Data
Apr 21, 2017: Cempra Presents Data at ECCMID Highlighting Need for New CABP Therapies and Activity of Solithromycin in Key Population Groups
Apr 13, 2017: Nabriva Therapeutics to present data at ECCMID supporting ongoing Phase 3 clinical development program for lefamulin
Apr 11, 2017: Nabriva Therapeutics Announces Enrollment Completion for LEAP 1, a Phase 3 Clinical Trial Evaluating Lefamulin in Community-Acquired Bacterial Pneumonia
Apr 03, 2017: Paratek Announces Positive Phase 3 Study of Omadacycline in Community-Acquired Bacterial Pneumonia
Mar 28, 2017: Cempra Withdraws Solithromycin Marketing Authorization Application in Europe
Feb 02, 2017: Nabriva Therapeutics Confirms No Sample Size Adjustment Required for LEAP 1 Phase 3 Trial of Lefamulin in Community Acquired Bacterial Pneumonia
Jan 18, 2017: Paratek Announces Completion of Enrollment in Omadacycline Phase 3 Community-Acquired Bacterial Pneumonia Study
Dec 29, 2016: Cempra Receives Complete Response Letter From FDA For Solithromycin NDAs
Dec 20, 2016: Nabriva Achieves 60% Randomization Target in LEAP 1 Phase 3 Trial in Community Acquired Bacterial Pneumonia
Dec 13, 2016: Paratek Advances Timing of Top-Line Data for Phase 3 Community Acquired Bacterial Pneumonia Study to the Second Quarter of 2017
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables


Number of Products under Development for Community Acquired Pneumonia, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Community Acquired Pneumonia - Pipeline by Aridis Pharmaceuticals LLC, H2 2017
Community Acquired Pneumonia - Pipeline by Biotest AG, H2 2017
Community Acquired Pneumonia - Pipeline by InflaRx GmbH, H2 2017
Community Acquired Pneumonia - Pipeline by ioGenetics Inc, H2 2017
Community Acquired Pneumonia - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2017
Community Acquired Pneumonia - Pipeline by Melinta Therapeutics Inc, H2 2017
Community Acquired Pneumonia - Pipeline by Merck & Co Inc, H2 2017
Community Acquired Pneumonia - Pipeline by Nabriva Therapeutics AG, H2 2017
Community Acquired Pneumonia - Pipeline by Paratek Pharmaceuticals Inc, H2 2017
Community Acquired Pneumonia - Pipeline by TaiGen Biotechnology Co Ltd, H2 2017
Community Acquired Pneumonia - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017
Community Acquired Pneumonia - Pipeline by Tetraphase Pharmaceuticals Inc, H2 2017
Community Acquired Pneumonia - Pipeline by TiGenix NV, H2 2017
Community Acquired Pneumonia - Pipeline by Wockhardt Ltd, H2 2017
Community Acquired Pneumonia - Dormant Projects, H2 2017
Community Acquired Pneumonia - Discontinued Products, H2 2017

List Of Figures


Number of Products under Development for Community Acquired Pneumonia, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Targets, H2 2017
Number of Products by Stage and Targets, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

Community Acquired Pneumonia - Pipeline Review, H2 2017 Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Community Acquired Pneumonia - Pipeline Review, H2 2017, provides an overview of the

View Report

Community Acquired Pneumonia -Pipeline Insights, 2017, report provides comprehensive insights about pipeline drugs across this Community Acquired Pneumonia. The key objective of the report is to establish the understanding

View Report

Global Cloud Infrastructure Market, By [ Equipment (Storage, Computing Systems, Network Infrastructure), Services (IaaS, PaaS, Managed Hosting, Application Delivery Network, Colocation Services), Deployment Model (Private Cloud, Public Cloud, Community Cloud, Hybrid Cloud), Verticals, Regions ] - Trends & Forecast – 2015–2020 market research report at USD 3500 and market update available at JSB Market Research.

View Report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports